You are here:
QUANTITATIVE TOXICOPROTEOMIC ANALYSIS OF CARCINOGEN-TREATED ANIMAL TISSUES AND HUMAN CELLS FOR HUMAN HEALTH RISK ASSESSMENT
Citation:
GE, Y., R. D. OWEN, AND J. PRESTON. QUANTITATIVE TOXICOPROTEOMIC ANALYSIS OF CARCINOGEN-TREATED ANIMAL TISSUES AND HUMAN CELLS FOR HUMAN HEALTH RISK ASSESSMENT. Presented at 2007 Annual Meeting of American Electrophoresis Society, Salt Lake City, UT, November 04 - 09, 2007.
Impact/Purpose:
research presentation
Description:
Humans are exposed to a variety of environmental toxicants, and this together with a large number of interacting factors can contribute to an individual's risk for health. To understand the toxic mechanisms and/or modes of action for human health risk assessment, molecular characterization of the proteome is required for a complete understanding of chemical-induced toxic responses. As an integration of proteomics, toxicology, and bioinformatics, toxicoproteomics focuses on proteome changes in cells or tissues following exposure to toxicants and aids in identifying the changes that may be important to disease development. To apply quantitative toxicoproteomic analysis to the identification of toxic mechanisms and modes of action as well as to biomarkers of exposure, toxicity, and effect for human health risk assessment, we have developed an integrated toxicoproteomic platform. This platform has been applied to the analysis of the effects of several environmental carcinogens such as arsenic, bromate, benzo[a]pyrene, and conazoles on protein expression, phosphorylation, and oxidation in mouse and rat liver, lung, thyroid, and kidney and in human cells. Our results demonstrate that toxicoproteomics has the potential to be a powerful tool to detect the "fingerprints" of specific toxic effects, and thereby to facilitate the identification and development of biomarkers for risk assessment.